Role and challenges of proteomics in pharma and biotech: technical, scientific and commercial perspective

References

• Lander ES, Linton LM, Birren B et al. Initial sequencing and analysis of the human genome.Nature409(6822), 860–921 (2001).
   PubMed Web of Science ®Google Scholar
• Venter JC, Adams MD, Myers EW et al. The sequence of the human genome.Science291(5507), 1304–1351 (2001).
   PubMed Web of Science ®Google Scholar
• Mattick JS. The human genome and the future of medicine.Med. J. Aust.179(4), 212–216 (2003).
   PubMedGoogle Scholar
• Wilkins MR, Sanchez, JC, Gooley, AA et al. Progress with proteome projects: why all proteins expressed by a genome should be identified and how to do it.Biotechnol. Genet. Eng. Rev.13, 19–50 (1996).
   PubMed Web of Science ®Google Scholar
• Patterson SD, Aebersold RH. Proteomics: the first decade and beyond.Nature Genet.33(Suppl.), 311–323 (2003).
   PubMed Web of Science ®Google Scholar
• Bilello JA. The agony and ecstasy of “omic” technologies in drug development.Curr. Mol. Med.5(1), 39–52 (2005).
   PubMed Web of Science ®Google Scholar
• Loo JA. The tools of proteomics.Adv. Protein Chem.65, 25–56 (2003).
   PubMedGoogle Scholar
• Guerrera IC, Kleiner O. Application of mass spectrometry in proteomics.Biosci. Rep.25(1/2), 71–93 (2005).
   PubMed Web of Science ®Google Scholar
• MacCoss MJ, Yates JR. Proteomics: analytical tools and techniques.Curr. Opin. Clin. Nutr. Metabol. Care4(5), 369–375 (2001).
   PubMedGoogle Scholar
• Aebersold R, Mann M. Mass spectrometry-based proteomics.Nature422(6928), 198–207 (2003).
   PubMed Web of Science ®Google Scholar
• Dhingra V, Gupta M, Andacht T, Fu ZF. New frontiers in proteomics research: a perspective.Int. J. Pharm.299(1–2), 1–18 (2005).
   PubMed Web of Science ®Google Scholar
• Issaq, HJ, Conrads TP, Janini GM, Veenstra TD. Methods for fractionation, separation and profiling of proteins and peptides.Electrophoresis23(17), 3048–3061 (2002).
   PubMed Web of Science ®Google Scholar
• Lee WC, Lee KH. Applications of affinity chromatography in proteomics.Anal. Biochem.324(1), 1–10 (2004).
   PubMed Web of Science ®Google Scholar
• Hunt DF, Henderson RA, Shabanowitz J et al. Characterization of peptides bound to the class I MHC molecule HLA-A2.1 by mass spectrometry.Science255(5049), 1261–1263 (1992).
   PubMed Web of Science ®Google Scholar
• Stoll D, Bachmann J, Templin MF, Joos TO. Microarray technology: an increasing variety of screening tools for proteomic research.Drug Discov. Today: Targets3(1), 24–31 (2004).
   Google Scholar
• Wang S, Sim TB, Kim Y-S, Chang Y-T. Tools for target identification and validation.Curr. Opin. Chem. Biol.8(4), 371–377 (2004).
   PubMed Web of Science ®Google Scholar
• Aebersold R. A mass spectrometric journey into protein and proteome research.J. Am. Soc. Mass Spectrom.14, 685–695 (2003).
   PubMed Web of Science ®Google Scholar
• Krijgsveld J, Heck AJR. Quantitative proteomics by metabolic labeling with stable isotopes.Drug Discov. Today: Targets3(2 Suppl.), S11–S15 (2004).
   Google Scholar
• Sechi S, Oda Y. Quantitative proteomics using mass spectrometry.Drug Discov. Today9(Suppl. 2), S41–S46 (2004).
   Google Scholar
• Ross PL, Huang YN, Marchese JN et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents.Mol. Cell. Proteomics3(12), 1154–69 (2004).
   PubMed Web of Science ®Google Scholar
• Figeys D. Proteomics in 2002: a year of technical development and wide-ranging applications.Anal. Chem.75(12), 2891–905 (2003).
   PubMedGoogle Scholar
• Jacobs JM, Adkins JN, Qian W-J et al. Utilizing human blood plasma for proteomic biomarker discovery.J. Proteome Res.4(4), 1073–1085 (2005).
   PubMed Web of Science ®Google Scholar
• Cho S, Park SG, Lee DH, Park BC. Protein–protein interaction networks: from interaction to networks.J. Biochem. Mol. Biol.37(1), 45–52 (2004).
   PubMedGoogle Scholar
• Auerbach D, Fetchko M, Stagljar. Proteomic approaches for generating comprehensive protein interaction maps.Drug Discov. Today: Targets2(3), 85–92 (2003).
   Google Scholar
• Burnet S, Thibault P, Gagnon E et al. Organelle proteomics: looking at less to see more.Drug Discov. Today9(2 Suppl.), S8–S18 (2004).
   PubMedGoogle Scholar
• Yates JR III, Gilchrist A, Howell KE, Bergeron JJ. Proteomics of organelles and large cellular structures.Nature Rev. Mol. Cell. Biol.6(9), 702–714 (2005).
   PubMed Web of Science ®Google Scholar
• Seo J, Lee KJ. Post-translational modifications and their biological functions: proteomic analysis and systematic approaches.J. Biochem. Mol. Biol.37(1), 35–44 (2004).
   PubMedGoogle Scholar
• Mann M, Jensen ON. Proteomic analysis of post-translational modifications.Nature Biotechnol.21(3), 255–61 (2003).
   PubMed Web of Science ®Google Scholar
• Righetti PG, Castagna A, Antonioli P, Boschetti E. Prefractionation techniques in proteome analysis: the mining tools of the third millennium.Electrophoresis26(2), 297–319 (2005).
   PubMed Web of Science ®Google Scholar
• Stasyk T, Huber LA. Zooming in: fractionation strategies in proteomics.Proteomics4(12), 3704–3716 (2004).
   PubMed Web of Science ®Google Scholar
• Dreger M. Subcellular proteomics.Mass Spectrom Rev.22(1), 27–56 (2003).
   PubMed Web of Science ®Google Scholar
• Gingras AC, Aebersold R, Raught B. Advances in protein complex analysis using mass spectrometry.J. Physiol.563(Pt 1), 11–21 (2005).
   PubMed Web of Science ®Google Scholar
• Reinders J, Sickmann A. State-of-the-art in phosphoproteomics.Proteomics5(16), 4052–4061 (2005).
   PubMed Web of Science ®Google Scholar
• Raman R, Raguram S, Venkataraman G, Paulson JC, Sasisekharan R. Glycomics: an integrated systems approach to structure–function relationships of glycans.Nature Methods2(11), 817–824 (2005).
   PubMed Web of Science ®Google Scholar
• Hanash S. Disease proteomics.Nature422(6928), 226–232 (2003).
   PubMed Web of Science ®Google Scholar
• Figeys D. Proteomics approaches in drug discovery.Anal. Chem.74(15), 412A–419A (2002).
   Google Scholar
• Petricoin EF, Zoon KC, Kohn EC, Barrett JC, Liotta LA. Clinical proteomics: translating benchside promise into bedside reality.Nature Rev. Drug Discov.1(9), 683–695 (2002).
   Google Scholar
• Humphery-Smith I, Dracup W. The search for validated biomarkers in the face of biosystems complexity.Drug Discovery World49–56 (2005).
   Google Scholar
• Baker M. In biomarkers we trust?Nature Biotechnol.23(3), 297–304 (2005).
   PubMed Web of Science ®Google Scholar
• Mankoff SP, Brander C, Ferrone S, Marincola FM. Lost in translation: obstacles to translational medicine.J. Transl. Med.2, 14–18 (2004).
   PubMedGoogle Scholar
• Zerhouni EA. US biomedical research: basic, translational and clinical sciences.JAMA294(11), 1352–1358 (2005).
   PubMed Web of Science ®Google Scholar
• Boguski MS, McIntosh MW. Biomedical informatics for proteomics.Nature422(6928), 233–237 (2003).
   PubMed Web of Science ®Google Scholar
• Souchelnytskyi S. Bridging proteomics and systems biology: what are the roads to be traveled?Proteomics5(16), 4123–4137 (2005).
   PubMed Web of Science ®Google Scholar
• Weston AD, Hood L. Systems biology, proteomics, and the future of health care: toward predictive, preventative, and personalized medicine.J. Proteome Res.3(2), 179–196 (2004).
   PubMed Web of Science ®Google Scholar
• Domon B, Broder S. Implications of new proteomics strategies for biology and medicine.J. Proteome Res.3(2), 253–260 (2004)
   PubMed Web of Science ®Google Scholar
• Reinders J, Lewandrowski U, Moebius J, Wagner Y, Sickmann A. Challenges in mass spectrometry-based proteomics.Proteomics4(12), 3686–3703 (2004).
   PubMed Web of Science ®Google Scholar
• Zolg JW, Langen H. How industry is approaching the search for new diagnostic markers and biomarkers.Mol. Cell. Proteomics3(4), 345–354 (2004).
   PubMed Web of Science ®Google Scholar
• Hochstrasser DF, Sanchez JC, Appel RD. Proteomics and its trends facing nature’s complexity.Proteomics2(7), 807–812 (2002).
   PubMed Web of Science ®Google Scholar
• Liggett W, Cazares L, Semmes OJ. A look at mass spectral measurement.Chance16(4), 24 (2003).
   Google Scholar
• Liggett WS, Barker PE, Semmes OJ, Cazares LH. Measurement reproducibility in the early stages of biomarker development.Dis. Markers20(6), 295–307 (2004).
   PubMedGoogle Scholar
• Calvo KR, Liotta LA, Petricoin EF. Clinical proteomics: from biomarker discovery and cell signaling profiles to individualized personal therapy.Biosci. Rep.25(1/2), 107–125 (2005).
   PubMed Web of Science ®Google Scholar
• Chaurand P, Sanders ME, Jensen RA, Caprioli RM. Proteomics in diagnostic pathology profiling and imaging proteins directly in tissue sections.Am. J. Pathol.165(4), 1057–1068 (2004).
   PubMed Web of Science ®Google Scholar
• Wetmore BA, Merrick BA. Toxicoproteomics: proteomics applied to toxicology and pathology.Toxicol. Pathol.32(6), 619–642 (2004).
   PubMed Web of Science ®Google Scholar
• Bandara LR, Kennedy S. Toxicoproteomics – a new preclinical tool.Drug Discov. Today7(7), 411–418 (2002).
   PubMed Web of Science ®Google Scholar
• Qoronfleh MW. Proteomics: the next frontier – a biotech perspective.J. Biomed. Biotechnol.2004(3), 121–123 (2004).
   PubMedGoogle Scholar